Long-term outcomes following CAR T cell therapy: what we know so far

Nature Reviews Clinical Oncology, Published online: 13 April 2023; doi:10.1038/s41571-023-00754-1Chimeric antigen receptor (CAR) T cells have dramatically improved the outcomes of patients with certain relapsed and/or refractory haematological malignancies. Owing to the promising short-term survival outcomes achieved, long-term data on both safety and survival are becoming increasingly relevant. In this Review, the authors describe the available long-term follow-up data from early studies testing the safety and efficacy of receiving CAR T cells targeting CD19 as well as more recent data on BCMA-targeted CAR T cells in patients with relapsed and/or refractory multiple myeloma.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research